CN108586484B - Thienopyran carboxamides and their use - Google Patents
Thienopyran carboxamides and their use Download PDFInfo
- Publication number
- CN108586484B CN108586484B CN201810537974.1A CN201810537974A CN108586484B CN 108586484 B CN108586484 B CN 108586484B CN 201810537974 A CN201810537974 A CN 201810537974A CN 108586484 B CN108586484 B CN 108586484B
- Authority
- CN
- China
- Prior art keywords
- thiopyran
- thieno
- dihydro
- oxo
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention belongs to the technical field of medicines, and relates to a thienothiopyran carboxamide compound, a preparation method thereof and application of the thienothiopyran carboxamide compound as an epidermal growth factor receptor tyrosine kinase inhibitor. The compounds, prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof, have the structure of formula (I): wherein R may be independently selected from hydrogen, C1-C6 alkyl; r 'and R' are independently selected from hydrogen, C1-C6 alkyl, substituted or unsubstituted phenyl, the substituent is C1-C4 alkyl, C1-C4 alkoxy, halogen, halogenated C1-C4 alkyl, halogenated C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, the substituent is dimethylamino, morpholinyl, methoxyphenoxy, methoxyphenyl, or R 'and R' form morpholinyl or piperidinyl together with the nitrogen atom to which they are attached.
Description
Technical Field
The invention belongs to the technical field of medicines, and relates to a thienothiopyran carboxamide compound, a preparation method thereof and application of the thienothiopyran carboxamide compound as an epidermal growth factor receptor tyrosine kinase inhibitor.
Background
The morbidity and mortality of various tumors in China have a remarkably rising trend in recent years, the tumors with the highest morbidity and mortality in men are lung cancer, and women are breast cancer and lung cancer. Unhealthy habits and habits such as smoking, excessive drinking, insufficient physical activities and the like, haze, and working and living pressure brought to people by rapid development of economic society and social transformation have inconsiderable influence on health, and the rising trend of the death rate of lung Cancer, liver Cancer, colorectal Cancer and breast Cancer related to environment and life style is more obvious, wherein the rising range of the lung Cancer and the breast Cancer is the largest, and the lung Cancer and the breast Cancer respectively rise by 465% and 96% in the last 30 years (StewartBW, Wild CP. WHO: World Cancer Report 2014. Lyon: International Agency for research on Cancer 2014.), so the prevention and the treatment of the lung Cancer and the breast Cancer are the hot spots of the current research.
Based on the differentiation degree and morphological characteristics of cancer cells, a large number of dysregulated epidermal growth factor signaling and overexpression of epidermal growth factor receptor tyrosine kinase are found in many tumor patients. Epidermal Growth Factor Receptor (EGFR), a member of the receptor type tyrosine kinase family, is known as a transmembrane glycoprotein consisting of an extracellular epidermal growth factor binding region (comprising 621 amino acid residues), a hydrophobic transmembrane domain (23 amino acid residues), an intracellular kinase region (542 amino acid residues), and a carboxy-terminal four part. EGFR has 4 types of HER-1, HER-2, HER-3 and HER-4, and when a small molecule ligand binds to EGFR, EGFR is activated, and then a tyrosine kinase region of EGFR is activated, a substrate enzyme for recognizing protein is activated, signals are transmitted into cells, and simultaneously after EGFR is activated, a plurality of downstream signal transduction paths can be activated to stimulate cell growth and proliferation (Zhang H, Berezv A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI ErbB receptors, from genes to target front cancer channels, the Journal of Clinical Investigation, 2007,117(8):2051 and 2058.). The receptor type tyrosine kinase mainly has the difference of an extracellular ligand binding region, and an intracellular tyrosine kinase structural domain has higher homology.
The existing epidermal growth factor receptor tyrosine kinase inhibitors, such as gefitinib, erlotinib, lapatinib and the like, have the skin reactions of diarrhea, rash, pruritus and the like, and possible headache, prolongation of heart QT interval, reduction of bioavailability and the like (Liyingying, Tianchi, Wanglie, Ximengmeng, Chengzeng, research progress of small molecule epidermal growth factor receptor tyrosine kinase inhibitors, tumor pharmacy, 2016,6(2): 81-88.).
The thienothiopyran carboxamide compound serving as an epidermal growth factor receptor tyrosine kinase inhibitor with a brand new structure type has the characteristics of novel structure type and equivalent or superior pharmacodynamic action to or to the existing medicaments, can be used for treating or preventing related diseases caused by dysregulation of epidermal growth factor receptor signal conduction, such as non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer and head and neck squamous cell carcinoma, and has good application value and development and application prospects.
Disclosure of Invention
The invention aims to provide a compound shown as a formula (I), a prodrug, a pharmaceutically active metabolite and a pharmaceutically acceptable salt thereof, and provides application of the compound in preparation of medicines for preventing and treating diseases related to EGFR signaling dysregulation.
The present invention provides compounds of formula (I), prodrugs and pharmaceutically acceptable salts thereof:
wherein the content of the first and second substances,
r may be independently selected from hydrogen, C1-C4 alkyl;
r 'and R' are independently selected from hydrogen, C1-C6 alkyl, substituted or unsubstituted phenyl, the substituent is C1-C4 alkyl, C1-C4 alkoxy, halogen, halogenated C1-C4 alkyl, halogenated C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, the substituent is dimethylamino, morpholinyl, methoxyphenoxy, methoxyphenyl, or R 'and R' form morpholinyl or piperidinyl together with the nitrogen atom to which they are attached.
Further, the present invention preferably relates to compounds represented by formula (I), prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof:
wherein the content of the first and second substances,
r may be independently selected from hydrogen, C1-C4 alkyl;
r ', R' are independently selected from hydrogen, C1-C4 alkyl, phenyl, C1-C4 alkyl substituted phenyl, C1-C4 alkoxy substituted phenyl, halogen substituted phenyl, trifluoromethoxyphenyl, dimethylaminopropyl, (4-morpholinyl) propyl, (2-methoxyphenoxy) ethyl, (3, 4-dimethoxyphenyl) ethyl, or R ', R' together with the nitrogen atom to which they are attached form a morpholinyl or piperidinyl group.
Still further, preferred compounds of the present invention are represented by formula (I), prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof:
wherein the content of the first and second substances,
r may be independently selected from hydrogen, methyl;
r ', R' are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, 4-methylphenyl, 2-ethylphenyl, 2-chlorophenyl, 4-trifluoromethoxyphenyl, 3-dimethylaminopropyl, 3- (4-morpholinyl) propyl, 2- (2-methoxyphenoxy) ethyl, 2- (3, 4-dimethoxyphenyl) ethyl, or R ', R' together with the nitrogen atom to which they are attached form a morpholinyl or piperidinyl group.
"pharmaceutically acceptable salts" refers to conventional acid addition salts or base addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed with suitable non-toxic organic or inorganic acids or organic or inorganic bases acid addition salts include hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, sulfate, perchlorate, thiocyanate, bisulfate, persulfate, borate, formate, acetate, propionate, valerate, pivalate, hexanoate, heptanoate, octanoate, isooctanoate, undecanoate, laurate, palmitate, stearate, oleate, cycloproponate, oxalate, malonate, succinate, maleate, fumarate, adipate, azelate, acrylate, strawberry, crotonate, tiglate, itaconate, sorbate, cinnamate, glycolate, lactate, malate, tartrate, citrate, tartrate, mandelate, prolinate, ascorbyl, gluconate, glucarate, mannitol, caseinate, phenate, cinnamate, phenate, phena.
The present invention also relates to pharmaceutical compositions for inhibiting epidermal growth factor receptor tyrosine kinase comprising a compound of formula I, prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
"pharmaceutically acceptable" such as pharmaceutically acceptable carriers, excipients, prodrugs, etc., means pharmacologically acceptable and substantially non-toxic to a patient to whom a particular compound is administered.
"pharmaceutically active metabolite" refers to a pharmaceutically acceptable and effective metabolite of a compound of formula I.
The term "halogen" as used in the present invention includes fluorine, chlorine or bromine.
"substituted," unless otherwise specified, means that the substituent may be present at one or more positions, the substituents being independently selected from a particular selection.
The compounds of the present invention, prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof, can be administered to a patient by various methods, such as orally in capsules or tablets, as sterile solutions or suspensions, and in some cases, intravenously as solutions. The free base compounds of the present invention may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts.
The thienothiopyran carboxamides, the prodrugs and the pharmaceutically acceptable salts thereof can be combined with the existing medicaments or used independently for preparing medicaments for treating related diseases of epidermal growth factor receptor signaling disorder.
The pharmaceutical composition can be combined with the existing medicines or used independently for preparing medicines for treating related diseases of epidermal growth factor receptor signal transduction disorder.
The epidermal growth factor receptor is HER-1, HER-2, HER-3 or HER-4, wherein the related diseases of the dysregulation of the epidermal growth factor receptor signal transduction are non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer or head and neck squamous cell carcinoma.
Methods of treatment and dosages used
The various diseases and conditions to be treated as described herein are well known and clear to those skilled in the art. It is also understood that one skilled in the art can treat a patient currently afflicted with a disease or condition with a therapeutically effective amount of the compound or affect the disease or condition by prophylactically treating a patient afflicted with a disease or condition.
The term "patient" as used herein refers to a warm-blooded animal, such as a mammal, having a tumor. It is understood that guinea pigs, dogs, cats, rats, mouse horses, cattle, sheep, and humans are examples of animals within the meaning of the term.
The term "therapeutically effective amount" as used herein refers to an amount effective for the control of tumor-associated diseases and conditions. The term "controlling" is intended to refer to all processes by which the progression of the diseases and conditions described herein can be slowed, interrupted, arrested or halted, and not necessarily the complete elimination of all of the symptoms of the disease and condition.
A therapeutically effective amount can be readily determined by the attending diagnostician as one skilled in the art using routine techniques and observing results obtained under analogous circumstances. In determining a therapeutically effective amount of a dosage, the attending diagnostician considers a number of factors, including but not limited to: the species of mammal; its size, age and general health; the specific diseases involved; the degree or complexity or severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; bioavailability characteristics of the administered formulation; a selected dosing regimen; concomitant medication use and other related conditions.
Therapeutically effective amounts of the active compounds are expected to vary from about 0.001 milligrams per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts can be determined by one skilled in the art.
In effectively treating patients suffering from the diseases and conditions described above, such compounds may be administered in any form or manner that makes the compound bioavailable in therapeutically effective amounts, including oral, inhaled, and parenteral routes. For example, the compounds can be administered orally, by inhalation as an aerosol or dry powder, by subcutaneous injection, intramuscular injection, intravenous injection, transdermal administration, intranasal administration, rectal administration, topical administration, and the like. Oral or inhalation administration is generally preferred for the treatment of respiratory diseases such as asthma. One skilled in the art of formulating formulations can readily select the appropriate form and mode of administration depending on the particular characteristics of the compound selected, the condition of the disease or condition to be treated, the stage of the disease or condition, and other relevant circumstances.
The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients in the form of pharmaceutical compositions, the proportions and properties of which are determined by the solubility and chemical properties of the compound selected, the route of administration selected, and standard pharmaceutical practice. The compounds of the present invention, while effective per se, may be formulated and administered in the form of their pharmaceutically acceptable salts, such as acid or base addition salts, for the purposes of stability, ease of crystallization, improved solubility, and the like.
The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound admixed or otherwise associated with one or more pharmaceutically acceptable carriers or excipients.
The pharmaceutical compositions are prepared according to methods well known in the pharmaceutical art. The carrier or excipient which may serve as a vehicle or medium for the active ingredient may be a solid, semi-solid, or liquid material. Suitable carriers or excipients are well known in the art. The pharmaceutical compositions may be adapted for oral, inhalation, parenteral or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions and the like.
The compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier, which may be enclosed in capsules or compressed into tablets. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These formulations should contain at least 4% of the compound of the invention, i.e. the active ingredient, but may vary depending on the particular form, conveniently between 4% and about 70% by weight of the unit. The amount of the compound present in the composition should be such that a suitable dosage is obtained. Preferred compositions and formulations of the present invention may be determined by one skilled in the art.
The tablets, pills, capsules, lozenges and the like may further contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other, different materials that modify the physical form of the dosage unit, for example as a coating. Syrups, in addition to containing the compound, may contain sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. The materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For parenteral administration, the compounds of the invention may be added to a solution or suspension. These formulations should contain at least 0.1% of the compound of the invention, but may vary between 0.1 and about 50% by weight of the formulation. The amount of compound present in such compositions should be such that a suitable dosage is obtained. Preferred compositions and vitex negundo can be determined by a person skilled in the art.
The compounds of the invention may also be administered by inhalation, for example as an aerosol or dry powder. May be released by a liquefied or compressed gas or by a suitable pumping system which dispenses the compounds of the invention or their formulations. Formulations for administration by inhalation of the compounds may be delivered in monophasic, biphasic or triphasic systems. For aerosol administration of the compounds, a number of systems are available. Dry powder formulations are prepared by granulating or milling the compound to the appropriate particle size or by mixing the granulated or milled compound with a suitable carrier, such as lactose or the like. Delivery systems by inhalation include the necessary containers, active agents, valves, sub-containers, and the like. Preferred aerosol and dry powder formulations for administration by inhalation can be determined by one skilled in the art.
The compounds of the invention may also be administered topically, in which case the carrier will suitably comprise a solution, ointment or gel base. The base may, for example, comprise one or more of the following substances: the concentration of the calcium-containing compound or pharmaceutically acceptable salt thereof in the topical formulation may be from about 0.1 to about 10% w/v (weight per unit volume).
The solution or suspension may also contain one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as vitamin C or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the osmotic pressure such as sodium chloride or glucose. The parenteral formulations may be presented in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Detailed Description
The following reaction scheme outlines the preparation steps for preparing the compounds of the present invention.
Reaction scheme
The present invention is described in detail by the following examples. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described.
Example 1: preparation of N-ethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide step a: preparation of 3- (thiophene-2-thio) propionic acid
Adding 0.04mol of 2-mercaptothiophene, 0.04mol of acrylic acid and 80mL of tetrahydrofuran into a 250mL round bottom flask, dropwise adding 11mL of triethylamine while stirring, heating and refluxing for reaction for 12h, after the reaction is finished, slightly cooling, and evaporating the tetrahydrofuran. After cooling, 40mL of ethyl acetate and 20mL of water were added, the pH of the solution was adjusted to 2 with 18% hydrochloric acid, the organic layers were collected, the aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling, precipitating a brown solid, and recrystallizing by using petroleum ether to obtain a white solid with the yield of 5.82g and the yield of 77.4%. m.p. 43-45 ℃.
And B: preparation of 5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
A250 mL three-necked flask was charged with 0.02mol of 3- (thiophene-2-thio) propionic acid, 20mL of dichloromethane, and 2 drops of DMF, and a dichloromethane solution containing oxalyl chloride (2.2 mL of oxalyl chloride, 15mL of dichloromethane) was added dropwise with stirring under nitrogen protection and stirred at room temperature for 2 hours. The reaction mixture was cooled to-10 ℃ or lower with an ice salt bath, and a dichloromethane solution containing tin tetrachloride (1.15 mL of tin tetrachloride, 10mL of dichloromethane) was added dropwise with stirring. After the dripping is finished, stirring is carried out for 2h at the temperature of 0 ℃. To a three-necked flask, 30mL of water was added, the organic layer was extracted, the aqueous layer was extracted with dichloromethane, and the organic layers were combined. The organic layer was washed with a saturated sodium carbonate solution, water and a saturated sodium chloride solution in this order, and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling to obtain a brown crude product, and recrystallizing by using petroleum ether to obtain a light yellow solid, wherein the yield is 2.75g and 80.9%. m.p. 59.0-60.5 ℃.1H-NMR(300MHz,DMSO-d6):δ2.77(t,2H,J＝6.6 Hz),3.47(t,2H,J＝6.6Hz),7.35(d,1H,J＝5.4Hz),7.38(d,1H,J＝5.4Hz)。MS(m/z):171.0([M+H]+)。
And C: preparation of 2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
0.06mol of aluminum trichloride and 20mL of methylene chloride were mixed, and the mixture was charged into a 250mL round-bottom flask and cooled in an ice bath. Dropwise adding dichloromethane solution containing trichloroacetyl chloride (trichloroacetyl chloride 0.026mol, dichloromethane 25mL) under stirring for about 20min, stirring for 30min, and continuously dropwise adding 5, 6-dihydro-4H-thieno [2,3-b ] containing 0.02mol under ice bath]20mL of a solution of thiopyran-4-one in methylene chloride was added dropwise, the mixture was stirred at room temperature for 24 hours, the reaction mixture was poured into 100mL of water, the organic layer was extracted, the aqueous layer was extracted with methylene chloride, and the organic layers were combined and dried over anhydrous magnesium sulfate. Filtering, evaporating the solvent from the filtrate, and recrystallizing with ethanol. Pale yellow crystals were obtained, yield 2.95g, yield 47.0%. m.p. 152.5-154.0 ℃.1H-NMR(600MHz,CDCl3)δ:2.92(t,2H,J＝6.6Hz), 3.45(t,2H,J＝6.6Hz),8.45(s,1H)；ESI-MS(m/z):312.9([M-H]-)。
Step D: preparation of 4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxylic acid
0.01mol of 2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] was added to a 250mL round-bottom flask]Reacting thiopyran-4-one, 0.013mol of sodium carbonate and 150mL of water at 60 ℃ for 15h, cooling to room temperature after the reaction is finished, performing suction filtration, adjusting the pH value of the filtrate to 2 by using hydrochloric acid, performing suction filtration, and washing the solid by using water to obtain a light yellow powdery solid, wherein the yield is 1.89g, the yield is 88.3%, and the m.p. is 201 and 203 ℃.1H-NMR(400MHz,DMSO-d6)δ:2.81(t,2H,J＝6.4Hz),3.45(t,2H, J＝6.4Hz),7.80(s,1H),13.43(s,1H)；ESI-MS(m/z):212.8([M-H]-)。
Step E: preparation of N-ethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Into a 50mL round-bottom flask, 1.5mmol of 4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] was added]Thiopyran-2-carboxylic acid, 1.5mmol of ethylamine, 1.9mmol of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, 0.3mmol of 1-hydroxybenzotriazole, 1mL of triethylamine and 15mL of dried methylene chloride were stirred at room temperature for 48 hours, filtered, the filtrate was washed with 18% hydrochloric acid, saturated sodium carbonate, water and saturated sodium chloride in this order, and the organic layer was extracted and dried over anhydrous magnesium sulfate. Vacuum filtering, evaporating solvent from filtrate to obtain crude product, and separating by silica gel column chromatographyAfter separation, 0.26g of white solid is obtained with a yield of 72.2%; mp 215-217 ℃; IR (KBr, cm)-1):3352.7,3080.6,3019.0,2969.7,2924.8, 2899.6,2866.1,1659.8,1630.0,1555.1,1517.5,1417.6,1398.5,1282.7, 1248.0,1184.6,1045.0,892.0,701.5,629.1；1H-NMR(600MHz,CDCl3)δ： 7.78(s,1H),6.28(s,1H),3.43～3.48(m,2H),3.39(t,J＝6.6Hz,2H),2.86(t,J ＝6.6Hz,2H),1.23(t,J＝7.2Hz,3H)；ESI-MS m/z:242.1([M+H]+), 264.0([M+Na]+),482.9([2M+H]+),482.9([2M+Na]+)。
Example 2: preparation of N-isopropyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis method of example 1, white solid is obtained with yield of 52.6%; mp 192-195 ℃; IR (KBr, cm)-1):3441.8,3350.7,3073.8,2970.5,2919.3,1660.6,1628.8, 1544.7,1511.9,1413.3,1395.5,1385.7,1273.8,1242.5,1127.1,893.0；1H-NMR(600MHz,CDCl3)δ：7.74(s,1H),6.04(d,J＝6.6Hz,1H), 4.17～4.25(m,1H),3.38(t,J＝6.0Hz,2H),2.86(t,J＝6.0Hz,2H),1.24(d,J＝ 6.6Hz,6H)；ESI-MS m/z:256.1([M+H]+),278.0([M+Na]+),293.9([M+K]+),510.8([2M+H]+),533.0([2M+Na]+)。
Example 3: preparation of N-butyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis procedure of example 1, a white solid was obtained in 32.5% yield; mp 223-225 ℃; IR (KBr, cm)-1):3440.7,3365.6,3072.3,2952.3,2926.9,2860.1,1658.3, 1627.7,1545.7,1511.4,1397.6,1288.1,1243.5,1041.9,887.8,705.8；1H-NMR(600MHz,CDCl3)δ：7.72(s,1H),6.07(s,1H),3.38～3.43(m,4H), 2.86(t,J＝6.0Hz,2H),1.55～1.60(m,2H),1.36～1.42(m,2H),0.95(t,J＝7.2 Hz,3H)；ESI-MS m/z:270.1([M+H]+),292.1([M+Na]+),538.9([2M+H]+),561.0([2M+Na]+)。
Example 4: preparation of N, N-diethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Pressing to realThe synthesis of example 1 gave 0.08g of yellow crystals in 20.1% yield; mp 147-148 ℃; IR (KBr, cm)-1):3432.4,2990.4,2944.7,2888.7,2813.4,2678.6, 2510.0,1656.5,1530.2,1401.4,1353.8,1282.5,1182.9,1039.5,744.2,704.3；1H-NMR(400MHz,CDCl3)δ：7.98(s,1H),3.38(t,J＝6.4Hz,2H),3.16(q,J＝ 7.2Hz,4H),2.84(t,J＝6.4Hz,2H),1.31(t,J＝7.2Hz,6H)；ESI-MS m/z: 270.1([M+H]+),292.1([M+Na]+),538.9([2M+H]+),561.0([2M+Na]+)。
Example 5: preparation of N- (4-methylphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Following the synthesis procedure of example 1, a yellow solid was obtained in 60.2% yield; mp 266-268 ℃; IR (KBr, cm)-1):3343.2,3076.4,2913.8,2855.2,1642.1,1597.5,1537.5, 1518.6,1414.0,1309.4,1314.7,1243.8,1187.4,1112.0,887.0,824.8,810.2；1H-NMR(600MHz,DMSO-d6)δ：10.28(s,1H),8.37(s,1H),7.60(d,J＝8.4 Hz,2H),7.15(d,J＝8.4Hz,2H),3.54(t,J＝6.0Hz,2H),2.82(t,J＝6.0Hz, 2H),2.27(s,3H)；ESI-MS m/z:302.2([M-H]-)。
Example 6: preparation of N- (2-ethylphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Following the synthesis procedure of example 1, a yellow solid was obtained in 21.3% yield; mp 131-133 ℃; IR (KBr, cm)-1):3320.4,3090.7,3059.1,2967.5,2932.0,2902.1,2872.0, 2813.4,1643.0,1537.5,1508.2,1395.6,1289.1,1244.2,1188.5,890.7,741.6；1H-NMR(600MHz,CDCl3)δ：7.89(s,1H),7.81(d,J＝7.2Hz,1H),7.72(s, 1H),7.24(d,J＝7.2Hz,2H),7.18(t,J＝7.2Hz,1H),3.41(t,J＝6.0Hz,2H), 2.87(t,J＝6.0Hz,2H),2.67(q,J＝7.8Hz,2H),1.27(t,J＝7.8Hz,3H)；ESI-MS m/z:316.0([M-H])。
Example 7: preparation of N- (2-chlorophenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Following the synthesis procedure of example 1, a yellow solid was obtained in 8.2% yield; mp 165-167 ℃; IR (KBr, cm)-1):3418.6,3024.2,2916.2,2807.2,1601.4,1531.3,1421.6, 1386.8,1240.6,1088.5,995.3,757.5,719.1,700.1；1H-NMR(400MHz, CDCl3)δ：8.42(d,J＝8.0Hz,1H),8.29(s,1H),7.92(s,1H),7.42(d,J＝8.0Hz, 1H),7.31(t,J＝8.0Hz,1H),7.09(t,J＝8.0Hz,1H),3.44(t,J＝6.4Hz,2H), 2.91(t,J＝6.4Hz,2H)；ESI-MS m/z:322.6([M-H]-)。
Example 8: preparation of N- (4-trifluoromethoxyphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
White crystals were obtained in 46.4% yield according to the synthesis method of example 1; mp 258-260 ℃; IR (KBr, cm)-1):3347.3,3074.9,2932.8,2793.5,1648.8,1549.7,1503.9, 1416.2,1392.4,1318.7,1263.7,1243.6,1190.5,1164.1,884.3,842.4,632.3；1H-NMR(600MHz,DMSO-d6)δ：10.52(s,1H),8.40(s,1H),7.84(d,J＝9.0 Hz,2H),7.37(d,J＝9.0Hz,2H),3.55(t,J＝6.0Hz,2H),2.83(t,J＝6.0Hz, 2H)；ESI-MS m/z:371.8([M-H]-)。
Example 9: preparation of N- (3-dimethylaminopropyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis procedure of example 1, a white solid was obtained in 19.9% yield; mp 137-138 ℃; IR (KBr, cm)-1):3360.3,3082.0,2943.1,2850.5,2809.7,2760.5,1549.5, 1516.3,1418.6,1402.3,1297.3,1252.0,1197.2,1040.6,979.5,888.7,739.8, 701.6,627.2；1H-NMR(600MHz,CDCl3)δ：8.73(s,1H),7.62(s,1H), 3.50～3.53(m,2H),3.38(t,J＝6.0Hz,2H),2.86(t,J＝6.0Hz,2H),2.50(t,J＝ 6.0Hz,2H),2.31(s,6H),1.70～1.74(m,2H)；ESI-MS m/z:299.1([M+H]+)。
Example 10: preparation of N- [3- (4-morpholinyl) propyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis method of example 1, a white solid is obtained with a yield of 70.6%; mp is 98-100 ℃; IR (KBr, cm)-1):3520.0,3379.8,3257.8,3079.4,2960.0,2935.3,2866.3, 1638.6,1553.0,1516.7,1396.7,1382.2,1304.3,1259.7,1145.4,1011.5, 873.3；1H-NMR(600MHz,CDCl3)δ：8.04(s,1H),7.95(s,1H),3.84～3.86(m, 4H),3.47～3.52(m,2H),3.38(t,J＝6.6Hz,2H),2.84(t,J＝6.6Hz,2H), 2.72～2.83(m,6H),1.90～1.96(m,2H)；ESI-MS m/z:341.1([M+H]+)。
Example 11: preparation of N- [2- (2-methoxyphenoxy) ethyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis method of example 1, white crystals are obtained with a yield of 51.9%; mp 153-155 ℃; IR (KBr, cm)-1):3363.5,3076.9,3008.5,2965.9,2918.7,2849.9,2831.4, 1659.6,1638.0,1590.3,1554.4,1504.5,1460.8,1283.4,1260.4,1244.2, 1208.3,1174.9,1123.0,1045.1,1021.8,1011.4,893.2,744.5；1H-NMR(600 MHz,CDCl3)δ：7.78(s,1H),6.90～7.01(m,5H),4.18(t,J＝4.8Hz,2H),3.93(s, 3H),3.78(q,J＝4.8Hz,2H),3.39(t,J＝6.0Hz,2H),2.86(t,J＝6.0Hz,2H)； ESI-MS m/z:361.9([M-H]-)。
Example 12: preparation of N- [2- (3, 4-dimethoxyphenyl) ethyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
According to the synthesis procedure of example 1, a white solid was obtained in 33.3% yield; mp 214-216 ℃; IR (KBr, cm)-1):3362.3,3079.1,2996.9,2930.1,2856.9,2832.8, 1667.4,1643.6,1555.9,1512.7,1458.8,1421.6,1396.7,1295.5,1242.7, 1186.8,1023.1,933.2,885.1,842.8,813.5,700.2；1H-NMR(600MHz, CDCl3)δ：7.65(s,1H),6.82(d,J＝9.0Hz,1H),6.75(s,1H),6.74(d,J＝9.0Hz, 1H),6.16(s,1H),3.87(s,3H),3.86(s,3H),3.63～3.66(m,2H),3.38(t,J＝6.0Hz,2H),2.83～2.86(m,4H)；ESI-MS m/z:278.1([M+H]+),400.1([M+Na]+)。
Example 13: preparation of 2- (4-morpholinoformyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 1, a white solid was obtained in 57.1% yield; mp 136-137 ℃; IR (KBr, cm)-1):3425.7,3304.9,3112.7,2979.5,2923.1,2898.6,2864.4, 1666.0,1592.6,1520.0,1433.7,1389.0,1274.4,1252.1,1233.2,1184.4, 1118.4,1046.5,1000.2,856.9,736.0；1H-NMR(600MHz,CDCl3)δ：7.57(s, 1H),3.75～3.78(m,4H),3.71～3.74(m,4H),3.39(t,J＝6.0Hz,2H),2.87(t,J＝ 6.0Hz,2H)；ESI-MS m/z:284.1([M+H]+),306.1([M+Na]+), 589.0([2M+Na]+)。
Example 14: preparation of 6, 6-dimethyl-N-tert-butyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
Step A: preparation of 3-methyl-3- (thiophene-2-thio) butanoic acid
Adding 0.04mol of 2-mercaptothiophene, 0.04mol of 3-methyl-2-butenoic acid and 80mL of tetrahydrofuran into a 250mL round-bottom flask, dropwise adding 11mL of triethylamine under stirring, and heating and refluxing for reaction for 20h under the protection of nitrogen to finish the reaction. Tetrahydrofuran was distilled off, after cooling, 40mL of ethyl acetate and water were added, the pH of the solution was adjusted to 2 with 18% hydrochloric acid, the organic layers were collected, the aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried over anhydrous magnesium sulfate. And (4) carrying out suction filtration, evaporating the solvent from the filtrate, cooling, precipitating a brown solid, and recrystallizing by using petroleum ether to obtain a white powdery solid with the yield of 5.47g and the yield of 63.35%. m.p. 58-59 ℃.
And B: preparation of 6, 6-dimethyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
A250 mL three-necked flask was charged with 0.02mol of 3-methyl-3- (thiophene-2-thio) butanoic acid, 20mL of dichloromethane, and 2 drops of DMF, and a dichloromethane solution containing oxalyl chloride (2.2 mL of oxalyl chloride, 15mL of dichloromethane) was added dropwise with stirring under nitrogen protection, followed by stirring at room temperature for 2 hours. The reaction solution was cooled in an ice salt bath, and a dichloromethane solution containing tin tetrachloride (1.15 mL of tin tetrachloride, 10mL of dichloromethane) was added dropwise with stirring. Stirring for 2 h. To a three-necked flask, 30mL of water was added, the organic layer was extracted, the aqueous layer was extracted with dichloromethane, and the organic layers were combined. The organic layer was washed with a saturated sodium carbonate solution, water and a saturated sodium chloride solution in this order, and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling to obtain a brown crude product, and recrystallizing with petroleum ether to obtain a light yellow powdery solid with the yield of 2.98g and the yield of 75.3%. m.p. 68-69 deg.C
And C: preparation of 6, 6-dimethyl-2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
0.06mol of threeAluminum chloride and 20mL of methylene chloride were mixed, added to a 250mL round bottom flask, and cooled in an ice bath. Dropwise adding dichloromethane solution containing trichloroacetyl chloride (trichloroacetyl chloride 0.026mol, dichloromethane 25mL) under stirring for about 20min, stirring for 30min, and continuously dropwise adding dichloromethane solution containing 6, 6-dimethyl-5, 6-dihydro-4H-thieno [2,3-b ] under ice bath]Solution of thiopyran-4-one in methylene chloride (6, 6-dimethyl-5, 6-dihydro-4H-thieno [2, 3-b)]0.02mol of thiopyran-4-one and 20mL of dichloromethane), stirring at room temperature for 24 hours after dropping, pouring the reaction mixture into 100mL of water, extracting an organic layer, extracting an aqueous layer with dichloromethane, combining the organic layers, and drying with anhydrous magnesium sulfate. Filtering, evaporating the solvent from the filtrate, and recrystallizing with ethanol. Yellow granular crystals were obtained with a yield of 3.25g, 43.3%. 157-159 ℃ in m.p. IR (KBr, cm)-1):3438,2965,2927,1662,1511, 1389,1242,1206,1041,961,885,848,809,714,700,677；1H-NMR(300 MHz,CDCl3):δ1.56(s,6H),2.81(s,2H),8.44(s,1H)；MS(m/z):345.1 ([M+H]+)。
Step D: preparation of 6, 6-dimethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxylic acid
Into a round-bottomed flask was added 0.01mol of 6, 6-dimethyl-2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] prepared as described above]Reacting thiopyran-4-one, 0.013mol of anhydrous sodium carbonate and water at 60 ℃ for 15h, cooling to room temperature after the reaction is finished, performing suction filtration, adjusting the pH value of the filtrate to 2 by using hydrochloric acid, performing suction filtration, and washing the solid by using water to obtain a light yellow powdery solid, wherein the yield is 2.16g, the yield is 78.83%, and the m.p. is 203 and 204 ℃. IR (KBr, cm)-1):3444,2964,2927,2360,2340,1663,1527, 1432,1398,1387,1295,1275,1204,1068,921,879,755,695；1H-NMR (300MHz,CDCl3):δ1.55(s,6H),2.80(s,2H),8.19(s,1H)；MS(m/z):243.0 ([M+H]+)，265.0([M+Na]+)。
Step E: preparation of 6, 6-dimethyl-N-tert-butyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide
In a 50mL round-bottom flask, 3mmol of 6, 6-dimethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] was added]Thiopyran-2-carboxylic acid, 3.3mmol of tert-butylamine, 3.8mmol of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride,0.59mmol of 1-hydroxybenzotriazole, 2mL of triethylamine and 20mL of dried dichloromethane were stirred at room temperature for 48 hours, filtered, and the filtrate was washed with 18% hydrochloric acid, saturated sodium carbonate, water and saturated sodium chloride in this order to extract an organic layer, which was dried over anhydrous magnesium sulfate. Suction filtration is carried out, the solvent is evaporated from the filtrate to obtain a crude product, and the crude product is separated by silica gel column chromatography to obtain 0.48 g of white solid with the yield of 53.87%. m.p. 206-. IR (KBr, cm)-1):3357,2956,2923,1651, 1638,1541,1508,1457,1410,1393,1303,1278,1214,1177,1128,885,586；1H-NMR(300MHz,CDCl3):δ1.44(s,9H),1.52(s,6H),2.76(s,2H),5.83 (s,1H),7.63(s,1H)；MS(m/z):298.3([M+H]+)，320.2([M+Na]+)。
Pharmacological examples
Example 15: inhibition effect on human lung adenocarcinoma cells A549 and human large cell lung cancer cells NCI-H460
Positive drug: gefitinib, available from Dalian Meiren Biotechnology Ltd.
Cell lines: human lung adenocarcinoma cells a 549; human large cell lung carcinoma cell NCI-H460 (Shanghai cell Bank of Chinese academy).
Cell culture conditions: RMPI1640 medium: fetal bovine serum 1:9, penicillin: 100 units/mL; streptomycin: 100 units/mL. At 37 ℃ with 5% CO2And (5) culturing and subculturing in a constant-temperature incubator.
Main reagents for the test: RMPI1640 medium (GIBCO, usa); fetal bovine serum (Hyclone, USA); pancreatin (Sigma, usa); thiazole blue (MTT, Sigma, usa);
main instruments for the test: autoclave SN510C (YAMATO, japan); CO2 incubator (SANYO, Japan), inverted microscope (CKX31, OLYMPUS, Japan), enzyme labeling photometer (MULTISKAN MC, England).
The test method comprises the following steps: the test drug (stock solution concentration: 4mM) was first prepared into a solution of 80. mu.M using RM 1640. After the cells are cultured to a logarithmic growth phase, digesting adherent cells for about 5min by using 0.25% pancreatin digestive juice, adding 10% fetal calf serum RMPI1640 culture medium to stop digestion, blowing and beating the cells into a cell suspension, transferring the cell suspension into a 15mL centrifuge tube, performing 1000-turn centrifugation for 5min (the suspension growth cells do not need to be digested, directly transferring the cell suspension into the 15mL centrifuge tube, performing 1000-turn centrifugation for 5min), discarding the supernatant, adding 10% fetal calf serum RMPI1640 culture medium, blowing and beating the cell suspension uniformly to prepare a single cell suspension, and adjusting the concentration of the cell suspension to be 3.0 multiplied by 10 by uniformly4Spreading the cell suspension in a 96-well plate at a concentration of 200. mu.L/well, wherein each group has 3 wells; 3 wells were left separately and 200. mu.L of each 10% fetal bovine serum RMPI1640 medium was added as blank control wells. After further culturing for 24h, adding 2 mu L of the test drug with the concentration of 80 mu M into each group of the experimental group; RMPI 16402 μ L was added to the control group; and (3) continuing culturing for 24h, taking out the culture plate 4h before finishing culturing, adding 20 mu L of MTT (methanol to toluene) of 5mg/ml into each hole (keeping out of the sun), continuing culturing, after finishing culturing, absorbing and removing the culture medium, adding 150 mu L of DMSO into each hole, shaking up uniformly, and measuring the absorbance value on a microplate reader at the wavelength of 562 nm. Repeat 3 times.
The cell growth inhibition rate calculation formula is as follows: the growth inhibition rate was ═ 1- (experimental absorbance average-blank absorbance average)/(control absorbance average-blank absorbance average) ] × 100%.
The experiment performed on the compound of the invention shows that the compound has an inhibitory effect on the cell proliferation of human lung adenocarcinoma cells A549 with high EGFR expression and human large cell lung cancer cells NCI-H460, and the inhibition rate is listed as follows:
example 16: inhibition of human breast cancer cells MCF-7
The experimental method comprises the following steps: human breast cancer cell MCF-7 is used as a test cell line and cultured in RPM I-1640 culture solution containing 10% (w) fetal calf serum for 24 hours at 37 ℃ in a CO2 culture box with the volume fraction of 5%. Cells in logarithmic growth phase (1.5X 10) were taken4one/mL) was inoculated into a 96-well plate at a concentration of 100. mu. mol. multidot.L per well-1And measuring the light absorption value of the target compound and the positive control drug tamoxifen at 490nm by using an enzyme-labeling instrument. According to the formula: the cell growth inhibition rate was 1- (number of cells in addition well/number of cells in control well) × 100%, and the cell growth inhibition rate at a concentration of 100 μ M was calculated. The inhibition rates for some samples were as follows:
the experimental result shows that the screened partial compounds have the inhibiting effect on the growth of human breast cancer cells MCF-7 at the concentration of 100 mu M.
In examples 17-37, "active compound" refers to a compound of formula I, or a salt or solvate thereof. The following non-limiting examples illustrate formulations for different topical administration modes. In formulations for transdermal administration, the active compound is generally used in an amount of 0.001 to 0.2% w/w), preferably 0.01 to 0.1% w/w).
Example 17: tablet formulation
25-1000mg of active compound, 45mg of starch, 35mg of microcrystalline cellulose, 4mL of polyvinylpyrrolidone (as a 10% aqueous solution), 4.5mg of sodium carboxymethylcellulose, 0.5mg of magnesium stearate, and 1mg of talc.
Example 18: suspending agent formula
0.1-1000mg of active compound, 50mg of sodium carboxymethylcellulose, 1.25mg of syrup, 0.1mg of sodium benzoate, a proper amount of flavoring agent and a proper amount of coloring agent, and adding pure water to 5 mL.
Example 19: aerosol formulations
0.25mg of active compound, 25-75mL of ethanol and 70mg of propellant 22 (chlorodifluoromethane).
Example 20: suppository formula
250mg of active compound, 2000mL of saturated fatty acid glycerides.
Example 21: injectable formulation
50mg of active compound, 1000mL of isotonic saline solution.
Example 22: ointment formulation
0.025g of micronized active compound, 10g of liquid paraffin, and 100g of soft white wax.
Example 23: ointment formulation
0.025g of active compound, 5g of propylene glycol, 5g of sorbitan sesquioleate, 10g of liquid paraffin and 100g of soft white wax.
Example 24: oil-in-water cream formulation
0.025g of active compound, 5g of cetyl alcohol, 5g of glycerol monostearate, 10g of liquid paraffin, 10002 g g of Ce tomacriol, 0.1g of citric acid, 0.2g of sodium citrate, 35g of propylene glycol and water to 100 g.
Example 25: oil-in-water cream formulation
0.025g of micronized active compound, 15g of soft white wax, 5g of liquid paraffin, 5g of cetyl alcohol, 2g of Sorbimcarol stearate, 0.5g of sorbitan monostearate, 0.2g of sorbic acid, 0.1g of citric acid, 0.2g of sodium citrate, and water to 100 g.
Example 26: water-in-oil cream formulation
0.025g of active compound, 35g of soft white wax, 5g of liquid paraffin, 5g of sorbitan sesquioleate, 0.2g of sorbic acid, 0.1g of citric acid and 0.2g of sodium citrate, and water is added until the weight is 100 g.
Example 27: lotion formulation
0.25g of active compound, 0.5mL of isopropanol, 3mg of carboxyvinyl polymer, a suitable amount of NaOH and water to 1 g.
Example 28: suspension formulation for injection
0.05-10mg of active compound, 7mg of sodium carboxymethylcellulose, 7mg of NaCl, 0.5mg of polyoxyethylene (20) sorbitan monooleate, 8mg of benzyl alcohol, and sterile water to 1 ml.
Example 29: aerosol formulation for oral and nasal inhalation
0.1% w/w active compound, 0.7% w/w sorbitan trioleate, 24.8% w/w trichlorofluoromethane, 24.8% w/w dichlorotetrafluoroethane and 49.6% w/w dichlorodifluoromethane.
Example 30: atomized solution formulation
7mg of active compound, 5mg of propylene glycol, water to 10 g.
Example 31: powder formulations for inhalation
Gelatine capsules were filled with a mixture of the following ingredients, micronised active compound 0.1mg, lactose 20mg and the powder was inhaled with the aid of an inhalation device.
Example 32: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound per dose.
Example 33: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound and 1mg of micronized lactose per dose.
Example 34: capsule formulation
1.0 part of active compound, 321mg of small sugar spheres, 306.6 mg of Aquacoat ECD, 0.5mg of acetyl tributyl citrate, 800.1 mg of Tween-800, 100-5517.5 mg of Eudragit L, 1.8mg of triethyl citrate, 8.8mg of talcum powder and 0.lmg of defoamer MMS.
Example 35: capsule seedling formula
2.0mg of active compound, 305mg of small sugar spheres, Aquocoat ECD 305.0 mg, acetyl tributyl citrate 0.4mg, Tween-800.14 mg, Eudragit NE30D 12.6.6 mg, Eudragit S10012.6 mg, talc 0.l6 mg.
Example 36: enema formula
0.2mg of active compound, 25mg of sodium carboxymethylcellulose, 0.5mg of disodium ethylenediaminetetraacetate, 0.8mg of methylparaben, 0.2mg of propylparaben, 7mg of sodium chloride, 1.8mg of citric acid, 800.01 mg of tween-800, and 1mL of pure water.
Example 37: formulation containing liposome
A. Preparation of the instillation formulation
The synthesized dipalmitoyl lecithin (45mg), dimyristoyl lecithin (7mg), dipalmitoyl phosphatidylglycerol (1mg) and (active compound (5mg) were mixed in a glass tube, and all components were dissolved in chloroform with N2Adding an aqueous solution (0.9% NaCl) to the lipids, forming liposomes at a temperature above the phase inversion temperature of the lipids, the resulting suspension containing liposomes ranging in size from very small vesicles to 2 μm.
B. Preparation of formulations for inhalation
Liposomes were prepared as in example A, with an aqueous solution containing 10% lactose at a 7:3 lactose to lipid ratio. The liposome suspension was frozen with dry ice and freeze-dried, and the dried product was micronized, and the Mass Mean Aerodynamic Diameter (MMAD) of the resulting particles was about 2 μm.
The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. However, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the protection scope of the technical solution of the present invention.
Claims (7)
1. A compound of formula (I) and pharmaceutically acceptable salts thereof:
wherein the content of the first and second substances,
r is independently selected from hydrogen, C1-C6 alkyl;
r 'and R' are independently selected from hydrogen, substituted or unsubstituted phenyl, substituted or unsubstituted C1-C6 alkyl, wherein the substituent of the substituted or unsubstituted phenyl is C1-C4 alkyl, C1-C4 alkoxy, halogen, halogenated C1-C4 alkyl, halogenated C1-C4 alkoxy, and the substituent of the substituted or unsubstituted C1-C6 alkyl is dimethylamino, morpholinyl, methoxyphenoxy, methoxyphenyl, or R 'and R' form morpholinyl together with the nitrogen atom to which they are connected.
2. A compound of formula (I) according to claim 1 and pharmaceutically acceptable salts thereof:
wherein the content of the first and second substances,
r is independently selected from hydrogen, C1-C4 alkyl:
r ', R' are independently selected from hydrogen, C1-C4 alkyl, phenyl, C1-C4 alkyl substituted phenyl, C1-C4 alkoxy substituted phenyl, halogen substituted phenyl, trifluoromethoxyphenyl, dimethylaminopropyl, (4-morpholinyl) propyl, (2-methoxyphenoxy) ethyl, or taken together with the nitrogen atom to which they are attached form a morpholinyl group.
3. The compound of claim 1 and pharmaceutically acceptable salts thereof:
wherein R is independently selected from hydrogen, methyl;
r ', R' are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, 4-methylphenyl, 2-ethylphenyl, 2-chlorophenyl, 4-trifluoromethoxyphenyl, 3-dimethylaminopropyl, 3- (4-morpholinyl) propyl, 2- (2-methoxyphenoxy) ethyl, or R ', R' together with the nitrogen atom to which they are attached form a morpholinyl group.
4. A compound selected from the group consisting of:
n-ethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n-isopropyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n-butyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n, N-diethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- (4-methylphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- (2-ethylphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- (2-chlorophenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- (4-trifluoromethoxyphenyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- (3-dimethylaminopropyl) -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- [3- (4-morpholinyl) propyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- [2- (2-methoxyphenoxy) ethyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
n- [2- (3, 4-dimethoxyphenyl) ethyl ] -4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide;
2- (4-morpholinoformyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-N-tert-butyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxamide.
5. The process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof according to claim 1, wherein the reaction scheme is as follows:
wherein R, R ', R' are as defined in claim 1.
6. A pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 4 and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
7. Use of a compound according to any one of claims 1 to 4 and pharmaceutically acceptable salts thereof or a pharmaceutical composition according to claim 6 for the manufacture of a medicament for the treatment of a disease associated with dysregulation of epidermal growth factor receptor signalling, said disease associated with dysregulation of growth factor receptor signalling being non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer or head and neck squamous cell carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810537974.1A CN108586484B (en) | 2018-05-30 | 2018-05-30 | Thienopyran carboxamides and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810537974.1A CN108586484B (en) | 2018-05-30 | 2018-05-30 | Thienopyran carboxamides and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108586484A CN108586484A (en) | 2018-09-28 |
| CN108586484B true CN108586484B (en) | 2020-05-15 |
Family
ID=63629813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810537974.1A Active CN108586484B (en) | 2018-05-30 | 2018-05-30 | Thienopyran carboxamides and their use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108586484B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082757A (en) * | 1976-12-10 | 1978-04-04 | Warner-Lambert Company | Amides of 4-hydroxy-6H-thieno[2,3-b]thiopyran-5-carboxylic acid-7,7-dioxide |
| CN101503413A (en) * | 2009-03-06 | 2009-08-12 | 南昌航空大学 | Preparation of 5,6-dihydro-6-methieno [2,3-b] thiopyran-2-sulfonic acid amide-4-keto |
| EP1813618B1 (en) * | 2004-11-05 | 2013-07-03 | Crystal Pharma S.A.U | Method of obtaining derivatives of 4-(n-alkylamine)-5,6-dihydro-4h-thieno-[2,3-b]-thiopyran |
| CN103497202A (en) * | 2013-10-23 | 2014-01-08 | 武汉武药科技有限公司 | Synthetic method of dorzolamide hydrochloride intermediate |
| CN103980289A (en) * | 2014-05-20 | 2014-08-13 | 沈阳药科大学 | Thieno-thiopyrano pyrazole compound and pharmaceutical applications thereof |
-
2018
- 2018-05-30 CN CN201810537974.1A patent/CN108586484B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082757A (en) * | 1976-12-10 | 1978-04-04 | Warner-Lambert Company | Amides of 4-hydroxy-6H-thieno[2,3-b]thiopyran-5-carboxylic acid-7,7-dioxide |
| EP1813618B1 (en) * | 2004-11-05 | 2013-07-03 | Crystal Pharma S.A.U | Method of obtaining derivatives of 4-(n-alkylamine)-5,6-dihydro-4h-thieno-[2,3-b]-thiopyran |
| CN101503413A (en) * | 2009-03-06 | 2009-08-12 | 南昌航空大学 | Preparation of 5,6-dihydro-6-methieno [2,3-b] thiopyran-2-sulfonic acid amide-4-keto |
| CN103497202A (en) * | 2013-10-23 | 2014-01-08 | 武汉武药科技有限公司 | Synthetic method of dorzolamide hydrochloride intermediate |
| CN103980289A (en) * | 2014-05-20 | 2014-08-13 | 沈阳药科大学 | Thieno-thiopyrano pyrazole compound and pharmaceutical applications thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108586484A (en) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105153122B (en) | [(indol-3-yl) pyrimidine -2-base] aminophenyl propyl- 2- alkenylamide derivatives and salt, preparation method, application | |
| CN106916177B (en) | A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes | |
| BRPI0805826B1 (en) | spiro-substituted compounds, pharmaceutical composition and use | |
| CN104395319A (en) | Thienopyridone derivatives useful as activators of ampk | |
| CN108822126B (en) | Thienopyran formyl piperazine compound and medical application thereof | |
| WO2020233641A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
| CN103044395B (en) | Desloratadine-containing amino acid derivative as well as preparation method and application thereof | |
| CN114181161B (en) | (2- ((substituted oxy) phenyl) amino) pyrimidin-4-yl) aminobenzoyl derivative and preparation method and application thereof | |
| CN108586485B (en) | 1- (4-hydroxyiminothieno [2,3-b ] thiopyranoformyl) piperazine compound and application thereof | |
| CN110964078A (en) | Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof | |
| CN108484635B (en) | 4H-thieno [2,3-b ] thiopyran-4-one compound and application thereof | |
| CN110467616B (en) | Preparation and application of triazolopyrazine compound containing heteroaryl substituted pyridazinone structure | |
| CN108586484B (en) | Thienopyran carboxamides and their use | |
| CN109896986B (en) | Structure simplification of lignan natural product 4-O-methyl saururus chinensis alcohol, preparation method thereof, pharmaceutical composition thereof and application thereof | |
| EP1911451A1 (en) | Protein-kinase CK2 inhibitors and their therapeutic applications | |
| CN115477608B (en) | Tubulin inhibitor and preparation method and application thereof | |
| CN108822127B (en) | 4-hydroxyiminothieno [2,3-b ] thiopyran-2-carboxamides and their use | |
| US9902709B2 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| CN104530081B (en) | The azacyclo-derivant of rapamycin and purposes | |
| CN108822125B (en) | 1- (thieno [2,3-b ] thiopyranoformyl) -4-aliphatic alkyl piperazine compound and medical application thereof | |
| WO2019001307A1 (en) | Amide compound, composition containing same, and use thereof | |
| CN104292211A (en) | Desloratadine nitric oxide donor, and preparation method and application thereof | |
| CN114957270A (en) | S (+) -pranoprofen derivative and preparation method and application thereof | |
| EP4155304A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
| WO2022089400A1 (en) | Compound for targeted degradation of btk and anti-tumour use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |